Interferon alfacon-1

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 03.04.2022

Dieser Artikel auf Deutsch

Synonym(s)

Interferon alphacon-1

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Non-naturally occurring, synthetic, recombinantly produced interferon-alfa derivative derived from the consensus sequence of different interferon alfa variants (CIFN = consensus interferon).

IndicationThis section has been translated automatically.

Histologically confirmed chronic hepatitis in patients > 18 LJ in whom serum markers for hepatitis C virus (HCV) infection are present (e.g. patients with elevated serum transaminase levels without liver decompensation).

Limited indicationThis section has been translated automatically.

Pat. < 18 LJ (insufficient data!).

Dosage and method of useThis section has been translated automatically.

Adults: 3 times/week 9 μg s.c. as single injection. Between 2 consecutive doses should preferably be 48 hours.

Undesirable effectsThis section has been translated automatically.

Frequently flu-like general symptoms (fever, fatigue, chills, headaches, myalgia, sweating), reactions at the injection site (erythema)

ContraindicationThis section has been translated automatically.

Serious heart disease in general, epilepsy, severe psychiatric disorders (depression, suicidal tendencies), severe kidney or liver disease, chronic hepatitis in patients treated with immunosuppressive drugs or who have recently been treated (except short-term therapy with glucocorticoids).

PreparationsThis section has been translated automatically.

Inferax

Note(s)This section has been translated automatically.

Remember! If a permanent or recurrent ADR develops after appropriate adjustment of the dose, or if the condition worsens, discontinue treatment.

Authors

Last updated on: 03.04.2022